Serological response to vaccination in post-acute sequelae of COVID

BMC Infectious Diseases

Table 1 Characteristics of the primary study samples

Characteristic	Prior COVID		P value
Characteristic	PASC	Recovered COVID	P value
N	245	86
Age in years, mean (SD)	48.7 (13.5)	42.0 (11.8)	< 0.001
Age in years, range	22 to 79	23 to 76
Male, n (%)	81 (33)	23 (27)	0.34
Non-Hispanic White, n (%)	124 (51)	34 (40)	0.10
Comorbidities,* n (%)
Autoimmune disorder	19 (8)	2 (2)	0.13
Cancer	15 (6)	3 (3)	0.52
Chronic Pulmonary Disease	1 (0)	8 (9)	< 0.001
Diabetes Mellitus	23 (9)	3 (3)	0.13
Hypertension	53 (22)	10 (12)	0.06
Elixhauser score, mean (SD)	0.8 (2.9)	0.7 (2.4)	0.77
Hospitalized for COVID-19, n (%)	54 (22)	0 (0)	< 0.001
Post-exposure monoclonal antibody infusion, n (%)	15 (6)	1 (1)	0.87
Days between infection onset and vaccination,† median [IQR]	131 [106, 242]	194 [63, 273]	0.12
SARS-CoV-2 vaccine type received, n (%)			< 0.001
Pfizer (monovalent)	125 (51)	86 (100)
Moderna (monovalent)	64 (26)	0 (0)
Johnson & Johnson	22 (9)	0 (0)
Other/Unknown	34 (14)	0 (0)

*Comorbidities were derived from the electronic medical record using previously validated Elixhauser definitions
†Vaccination is defined as the date of vaccine completion: second dose of a two-dose regimen, or dose of a single-dose regimen

ISSN: 1471-2334